Back to Newsroom
Back to Newsroom

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CAH, IFF and SRPT

Sunday, 15 September 2019 11:05 AM

The Gross Law Firm

Topic:
5

NEW YORK, NY / ACCESSWIRE / September 15, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Cardinal Health, Inc. (NYSE: CAH)

Investors Affected: March 2, 2015 - May 2, 2018

A class action has commenced on behalf of certain shareholders in Cardinal Health, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: 1) following Cardinal's acquisition of Cordis, the RFID [radio-frequency identification] inventory tracking technology and advanced supply chain solutions that Defendants told investors the Company would to use to improve Cordis’s performance were never implemented across Cordis; 2) Cordis’s antiquated and ineffective global supply chain was causing operational and inventory problems at Cordis; 3) as a result, Cordis manufactured and accumulated excessive amounts of cardiovascular product inventories, which sat on the shelf and became unsellable and/or expired; 4) the Company materially overstated Cordis’s inventory balances; 5) Cordis was not “performing well” and its integration was not “on track,” “going incredibly well” or “largely on plan"; and 6) to correct Cordis’s deficiencies, the Company would have to make substantial investments in Cordis’s IT and supporting infrastructure, thereby incurring significant Selling, General and Administrative Expenses charges beyond the levels internally budgeted or projected by Cardinal and diminishing operating earnings.

Shareholders may find more information at https://securitiesclasslaw.com/securities/cardinal-health-inc-loss-submission-form/?id=3505&from=1

International Flavors & Fragrances Inc. (NYSE: IFF)

Investors Affected: May 7, 2018 - August 5, 2019

A class action has commenced on behalf of certain shareholders in International Flavors & Fragrances Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) that Frutarom Industries Ltd. ("Frutarom"), which the Company acquired in 2018, had bribed customers in Russia and Ukraine; (2) that senior management at Frutarom were aware of such improper payments; (3) that, as a result, Frutarom’s financial results were materially overstated; (4) that, as a result of the improper payments, the Company was reasonably likely to face regulatory scrutiny; (5) that the Company had not completed adequate due diligence before acquiring Frutarom; (6) that, as a result of the foregoing, the Company was unlikely to achieve purported synergies from the acquisition; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/international-flavors-fragrances-inc-loss-submission-form/?id=3505&from=1

Sarepta Therapeutics, Inc. (NASDAQ: SRPT)

Investors Affected: September 6, 2017 - August 19, 2019

A class action has commenced on behalf of certain shareholders in Sarepta Therapeutics, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) golodirsen, Sarepta's drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen’s accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta’s public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/sarepta-therapeutics-inc-loss-submission-form/?id=3505&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm

Topic:
5
Back to newsroom
Back to Newsroom
Share by: